Evidence map›Paper›PMID 24622385›Full record

ArticleCirculation2014

Lipidomics profiling and risk of cardiovascular disease in the prospective population-based Bruneck study.

Christin Stegemann, Raimund Pechlaner, Peter Willeit, Sarah R Langley, Massimo Mangino, Ursula Mayr, Cristina Menni, Alireza Moayyeri, Peter Santer, Gregor Rungger and 4 more

Registry-linked trialOpen access · bronzeAbstract readTwin Study
PubMed Publisher
In one paragraph

Article in Circulation, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03378843 (Association Between Dietary Spermidine Intake and Mortality in the Population-based Bruneck Study), which is not on this map. Cited by 313 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
313citing papers in PubMed, 1 pooled it
16.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03378843 completednot on this map

Association Between Dietary Spermidine Intake and Mortality in the Population-based Bruneck Study

TypeobservationalSponsorMedical University InnsbruckRan1995 to 2015Enrolled829ConditionsHealthy Diet, MortalityArmsSpermidine content of natural diet
3 · Its place in the literature

Who cites it

313 citing papers in PubMed, 1 synthesis or guideline pooled it, 566 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Trial
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Review

253 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

14 authors at 2 institutions in 2 countries.

Christin StegemannKing's British Heart Foundation Centre (C.S., S.R.L., U.M., M. Mayr) and Department of Twin Research & Genetic Epidemiology (M. Mangino, C.M., A.M., T.D.R.), King's College London, London, UK; Department of Neurology, Medical University Innsbruck, Innsbruck, Austria (R.P., P.W., J.W., S.K.); Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK (P.W.); and Departments of Laboratory Medicine and Neurology, Bruneck Hospital, Bruneck, Italy (P.S., G.R.).
Raimund Pechlaner
Peter Willeit
Sarah R Langley
Massimo Mangino
Ursula Mayr
Cristina Menni
Alireza Moayyeri
Peter Santer
Gregor Rungger
Tim D Spector
Johann Willeit
Stefan Kiechl
Manuel Mayr
University of Cambridge · GBInnsbruck Medical University · AT

Funding

Austrian Science Fund FWF TRP 188British Heart Foundation FS/13/2/29892Wellcome Trust
6 · The paper itself

Abstract

backgroundThe bulk of cardiovascular disease risk is not explained by traditional risk factors. Recent advances in mass spectrometry allow the identification and quantification of hundreds of lipid species. Molecular lipid profiling by mass spectrometry may improve cardiovascular risk prediction. METHODS AND

resultsLipids were extracted from 685 plasma samples of the prospective population-based Bruneck Study (baseline evaluation in 2000). One hundred thirty-five lipid species from 8 different lipid classes were profiled by shotgun lipidomics with the use of a triple-quadrupole mass spectrometer. Levels of individual species of cholesterol esters (CEs), lysophosphatidylcholines, phosphatidylcholines, phosphatidylethanolamines (PEs), sphingomyelins, and triacylglycerols (TAGs) were associated with cardiovascular disease over a 10-year observation period (2000-2010, 90 incident events). Among the lipid species with the strongest predictive value were TAGs and CEs with a low carbon number and double-bond content, including TAG(54:2) and CE(16:1), as well as PE(36:5) (P=5.1 × 10⁻⁷, 2.2 × 10⁻⁴, and 2.5 × 10⁻³, respectively). Consideration of these 3 lipid species on top of traditional risk factors resulted in improved risk discrimination and classification for cardiovascular disease (cross-validated ΔC index, 0.0210 [95% confidence interval, 0.0010-0.0422]; integrated discrimination improvement, 0.0212 [95% confidence interval, 0.0031-0.0406]; and continuous net reclassification index, 0.398 [95% confidence interval, 0.175-0.619]). A similar shift in the plasma fatty acid composition was associated with cardiovascular disease in the UK Twin Registry (n=1453, 45 cases).

conclusionsThis study applied mass spectrometry-based lipidomics profiling to population-based cohorts and identified molecular lipid signatures for cardiovascular disease. Molecular lipid species constitute promising new biomarkers that outperform the conventional biochemical measurements of lipid classes currently used in clinics.

Indexed as

MetabolomicsAgedAged, 80 and overBiomarkersCardiovascular DiseasesCholesterol EstersFemaleHumansLipidosesLysophosphatidylcholinesMaleMass SpectrometryMiddle AgedMultivariate AnalysisPhosphatidylcholinesPhosphatidylethanolaminesBiomarkersCholesterol EstersLysophosphatidylcholinesPhosphatidylcholinesphosphatidylethanolaminePhosphatidylethanolaminesSphingomyelinsTriglyceridesbiomarkerscardiovascular diseaseslipidsmass spectrometrymetabolomics

Identifiers

PMID24622385
OpenAlexW2035598079

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.